期刊文献+

CA125、CA153、CA199和CEA联合检测在上皮性卵巢癌中的诊断价值 被引量:21

Diagnostic value of combined detection of CA125,CA153,CA199 and CEA in epithelial ovarian carcinoma
下载PDF
导出
摘要 目的探讨血清中CA125、CA153、CA199和CEA四项肿瘤标志物的联合检测在上皮性卵巢癌诊断中的价值。方法采用化学发光免疫测定法检测54例卵巢癌患者和68例卵巢良性病变患者手术前,以及55例对照组(无妇科疾病及恶性疾病)妇女的血清样本中CA125、CA153、CA199及CEA水平。应用统计软件SPSS 13.0和MedCalc 10.4.0.0回顾性分析检测结果。结果计算每种标志物单项及联合检测的敏感度、特异度及准确度。CA125三项指标分别为96.3%、64.7%和78.7%,高于其他单项指标。而联合检测中CA125联合CA153敏感度高达99.1%,准确度为79.5%,分别高于单项最佳的CA125及其他联合检测方式(P<0.05)。结论使用CA125与CA153联合检测对上皮性卵巢癌的诊断价值优于CA125单项检测及其他组合方式。 Objective To explore the value of the combined detection of four tumor markers of serum CA125,CA153,CA199 and CEA in the diagnosis of epithelial ovarian carcinoma(EOC).Methods The serum levels of CA125,CA153,CA199 and CEA were detected before operation in 54 cases of ovarian cancer and 68 cases of ovarial benign lesion and 55 healthy women as the con-trol group,by using chemiluminescent immunoassay(CLIA).The statistical software SPSS 13.0 and MedCalc 10.4.0.0 were used to retrospectively analyze the results.Results The sensitivity,specificity and accuracy of the single index detection and the com-bined detection were calculated.The sensitivity,specificity and accuracy of CA125 were 96.3%,64.7% and 78.7% respectively, which were higher than other single index′s.In the combine detection,the sensitivity and accuracy of the combined detection of CA125 and CA153 were 99.1% and 79.5% respectively,which were higher than those in the optimal single index CA125 and the other combined detection(P 〈0.05).Conclusion The combined detection of CA125 and CA153 is superior to the CA125 single in-dex detection in the diagnostic value for EOC.
作者 冯先华 郗娟
出处 《国际检验医学杂志》 CAS 2014年第14期1846-1847,1850,共3页 International Journal of Laboratory Medicine
关键词 上皮性卵巢癌 CA125 肿瘤标志物 联合检测 诊断 epithelial ovarian cancer CA125 tumor markers combined detection diagnosis
  • 相关文献

参考文献11

  • 1Moore RG,MacLaughlan S,Bast RC Jr. Current state of biomark- er development for clinical application in epithelial ovarian cancer [J]. Gynecol Oncol,2010,116(2) : 240-245.
  • 2Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial[J]. Ob- stet Gynecol, 2009,113 (4) : 775-782.
  • 3Bast RC Jr. Status of tumor markers in ovarian cancer screening [J]. J C/in Oncol,2003,21(Suppl 10) :200-205.
  • 4乐杰.妇产科学[M].7版.北京:人民卫生出版社,2009:92-99.
  • 5连丽娟.林巧稚妇科肿瘤学[M].3版.北京:人民卫生出版社,2006:461.
  • 6Moore RG, MacLaughlan S, Bast RC Jr. Current state of biomar- ker development for clinical application in epithelial ovarian cancer [J]. Gynecol Oneol, 2010,116(2) : 240-245.
  • 7Petri AL, Hogdall E,Christensen IJ, et al. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer[J].APMIS, 2006,114(5) :359- 363.
  • 8郭少磊,高美华,李武伦.CA125、CA72-4的检测在卵巢癌早期诊断中的临床价值[J].中国医疗前沿,2008,3(6):26-27. 被引量:7
  • 9邹红云,余伍忠,何江,刘丽,仇东辉,刘鸿春.12项肿瘤标志物联合检测在卵巢癌诊断中的应用分析[J].标记免疫分析与临床,2008,15(6):376-379. 被引量:4
  • 10Nolen B, Marrangoni A, Velikokhatnaya L. A serum based analy- sis of ovarian epithelial tumorigenesis[J]. Gynecologic Oncology, 2009,112(1) : 47-54.

二级参考文献7

共引文献243

同被引文献167

引证文献21

二级引证文献165

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部